• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Bayer Completes Sale of Its Environmental Science Professional Business to Cinven

Share:

October 11, 2022

Bayer has completed the sale of its Environmental Science Professional business to the international private equity firm Cinven, after the two companies had entered into a corresponding agreement in March. The conditions for closing the transaction – including the receipt of regulatory approval – have now been met. The purchase price for the business, which generated sales of approximately 600 million euros in 2021, amounts to 2.6 billion U.S. dollars.

“We thank the employees of Environmental Science Professional for their many years of commitment and the associated success of Bayer. In Cinven, we have found a strong new owner with a firm commitment to the long-term growth potential of the business and to its people,” said Rodrigo Santos, member of the Board of Management of Bayer AG and head of the Crop Science Division. “At the same time, we can concentrate on our core agricultural business and the successful implementation of our growth strategy in the Crop Science Division.” Bayer will use the net proceeds from the transaction to reduce its net financial debt.

The divested business is set to operate as an independent company called Envu. The business is a global leader offering solutions to control pests, disease and weeds in non-agricultural areas such as vector control, professional pest management, vegetation management, forestry, and turf and ornamentals. It is headquartered in Cary, North Carolina, United States, and is active in over 100 countries. Nearly 900 employees in total will transfer from Bayer to Envu.

“Envu is a global leader in a highly attractive and critical industry. We thank Bayer for the trust they have placed in Cinven and plan to build on the strong foundations established by Bayer by significantly investing in it,” said Pontus Pettersson, Partner at Cinven. “Cinven is excited to build an independent, focused company and is well positioned to continue to drive innovation and accelerate growth, including the delivery of digital and data-enabled solutions, and to extend the product portfolio further by creating innovative and sustainable solutions for its customers.”

Forward-Looking Statements

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Source: Biospace

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • CB Insights: AI Startup Funding Hit New High of $26.6 Billion in 2019CB Insights: AI Startup Funding Hit New High of $26.6 Billion in 2019
  • RTI Surgical® to Acquire Paradigm SpineRTI Surgical® to Acquire Paradigm Spine
  • CMS Launches $1.65M Artificial Intelligence Health Outcomes ChallengeCMS Launches $1.65M Artificial Intelligence Health Outcomes Challenge
  • COVID-19 Drug API Market is set for Lucrative GrowthCOVID-19 Drug API Market is set for Lucrative Growth
  • Innovus Pharmaceuticals Acquires Worldwide Rights to Four Products from Boston Topicals, LLCInnovus Pharmaceuticals Acquires Worldwide Rights to Four Products from Boston Topicals, LLC
  • Genesis Biotechnology Group Acquires Nedp to Grow the Preclinical Chemistry Services Portfolio of Genesis Drug Discovery & Development (gd3)Genesis Biotechnology Group Acquires Nedp to Grow the Preclinical Chemistry Services Portfolio of Genesis Drug Discovery & Development (gd3)
  • Consumers Cite Trump as Leading Driver of COVID-19 Vaccine SkepticismConsumers Cite Trump as Leading Driver of COVID-19 Vaccine Skepticism
  • Cognizant and XPRIZE Announce Finalists For $500k COVID-19 Pandemic Response CompetitionCognizant and XPRIZE Announce Finalists For $500k COVID-19 Pandemic Response Competition

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications